Cirrhosis

Approximately 14% of the U.S. population lives in rural areas, where access to health care may be limited by insurance coverage, geography and infrastructure, and provider shortages, according to HHS.

Metabolic surgery significantly lowered risk for major adverse liver outcomes vs. nonsurgical management among patients with obesity and compensated cirrhosis from metabolic dysfunction-associated steatohepatitis, according to study data.

Fecal microbiota transplant, regardless of dose or route, was safe and associated with reduced hepatic encephalopathy recurrence among patients with cirrhosis receiving lactulose and rifaximin, according to a study in Journal of Hepatology.

Hispanic patients hospitalized for alcohol use disorder were more likely to develop alcohol-associated hepatitis, decompensated cirrhosis and related complications compared with non-Hispanic white patients, according to published data.

The FDA has granted premarket approval to Sequana Medical’s alfapump implantable device for the treatment of recurrent or refractory ascites due to cirrhosis, according to a company press release.

The FDA granted fast track designation to Lipocine’s LPCN 1148, an oral androgen receptor agonist containing testosterone dodecanoate, for the treatment of sarcopenia in patients with decompensated cirrhosis, according to the manufacturer.

Incidence of hepatocellular carcinoma was significantly higher among cirrhotic patients coinfected with hepatitis B and D viruses compared with those with HBV alone, with researchers suggesting HDV “plays a direct role” in HCC occurrence.

Among veterans with chronic hepatitis B virus infection, rates of hepatitis D virus testing were low and those with concurrent infection were at greater risk for cirrhosis and hepatic decompensation, according to study results.

SAN DIEGO — Both FibroScan-aspartate aminotransferase and Agile 3+ scores “performed well” in predicting risk for advanced fibrosis in patients with metabolic dysfunction-associated steatohepatitis who had been treated with pegozafermin.

SAN DIEGO — Once-daily ALG-055009 achieved “significant and robust reductions” in liver fat at 12 weeks and was well-tolerated among noncirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to data.